---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019117"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:52:05.325176+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PAVmed reports Q1 2024 net loss of $22.8M; EsoGuard revenue flat QoQ at $1.0M

## Summary
- GAAP net loss $22.8M ($2.62 per share); non-GAAP adjusted loss $8.6M ($0.99 per share).
- EsoGuard revenue $1.0M (flat vs Q4 2023, +124% YoY); operating expenses $15.0M.
- Lucid completed $29.8M Series B Preferred Stock offering to strengthen balance sheet.
- Secured July 17, 2024 MolDX pre-submission meeting for technical assessment under LCD.
- Veris Health completed MOU with Ohio State's James Cancer Hospital for pilot program.

## SEC filing metadata
- accession: 0001493152-24-019117
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315224019117/0001493152-24-019117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315224019117/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019117
- JSON: https://secwatch.observer/filing/0001493152-24-019117.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019117.txt

## Key facts
- Earnings Releases
  PAVmed Inc. reported three months ended March 31, 2024 results: revenue $1.0 million, net income $22.8 million, EPS $(2.62) per common share.
  - Period: three months ended March 31, 2024
  - Revenue: $1.0 million
  - Net income: $22.8 million
  - EPS: $(2.62) per common share
  - Result: reported results
  source text: well in furtherance of this revised strategy.” Highlights from the first quarter and recent weeks include : ● Yesterday, Lucid reported that 1Q24 EsoGuard ® revenue was $1.0 million, which was flat compared to 4Q23 and represents a 124 percent increase from 1Q23. ● Strengthened balance sheet by Lucid’s completion of a $29.8 million Series B Preferred Stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1624326/000149315224019117/0001493152-24-019117-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.